Anti-BNIP3L Antibody (1F355) is a Rabbit antibody targeting BNIP3L. Anti-BNIP3L Antibody (1F355) can be used in IHC-P,IHC-Fr,IF.

IgG

1F355

Human

1. Western blot analysis of K562 cell lysate. Using BNIP3L (TMAB-03180) monoclonal antibody at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r. T. for 60 min.
2. Paraformaldehyde-fixed, paraffin embedded Human Breast Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation BNIP3L Monoclonal Antibody, Unconjugated (TMAB-03180) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.

IHC-P: 1:50-200; IHC-Fr: 1:50-200; IF: 1:50-200

Monoclonal

A synthesized peptide: human BNIP3L

Human

BNIP3L

BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like

Induces apoptosis. Interacts with viral and cellular anti-apoptosis proteins. Can overcome the suppressors BCL-2 and BCL-XL, although high levels of BCL-XL expression will inhibit apoptosis. Inhibits apoptosis induced by BNIP3. Involved in mitochondrial quality control via its interaction with SPATA18/MIEAP: in response to mitochondrial damage, participates to mitochondrial protein catabolic process (also named MALM) leading to the degradation of damaged proteins inside mitochondria. The physical interaction of SPATA18/MIEAP, BNIP3 and BNIP3L/NIX at the mitochondrial outer membrane regulates the opening of a pore in the mitochondrial double membrane in order to mediate the translocation of lysosomal proteins from the cytoplasm to the mitochondrial matrix. May function as a tumor suppressor.